TY - JOUR
T1 - Prevention and Recovery of COVID-19 Patients With Kampo Medicine
T2 - Review of Case Reports and Ongoing Clinical Trials
AU - Takayama, Shin
AU - Namiki, Takao
AU - Odaguchi, Hiroshi
AU - Arita, Ryutaro
AU - Hisanaga, Akito
AU - Mitani, Kazuo
AU - Ito, Takashi
N1 - Funding Information:
We thank the members of Japan Society for Oriental Medicine for the many proposals and suggestions for this project. Rie Ono named this project as the “IMJEDI study.” Natsumi Saito created the symbol for the “IMJEDI study.” Akiko Kikuchi provided suggestions for Figure 1. Tetsuharu Kamiya translated the name of Kampo medicines to Chinese. Soichiro Kaneko confirmed the references in Japanese, Chinese, and English. Akiko Kuwabara coordinated the clinical research process in Studies 2 and 3. Emiko Yoshida coordinated the clinical research process in Study 1. Akino Wakasugi and Mariko Sekine coordinated the clinical research process in Study 4.
Funding Information:
The authors declare that this study received funding from JSOM and TSUMURA and Co. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.
Publisher Copyright:
© Copyright © 2021 Takayama, Namiki, Odaguchi, Arita, Hisanaga, Mitani and Ito.
PY - 2021/6/23
Y1 - 2021/6/23
N2 - Coronavirus disease 2019 (COVID-19) spread to Japan in 2020, where the number of infected patients exceeded 250,000 and COVID-related deaths exceeded 3,500 in one year. Basic guidelines for infection control were implemented in Japan, and research and development of effective drugs and vaccines were promoted. This included considering Kampo medicine, which has a long history of treating recurring emerging viral infections. Considering the characteristics of the disease (inflammation of the upper and lower respiratory tract as well as potential neural damage and vasculitis), Kampo medicine could be considered as a treatment strategy due to its antiviral and anti-inflammatory effects induced by multiple active substances that could aid in disease prevention and recovery. In this study, case reports on the management of COVID-19 with Kampo medicine, which were published until March 31, 2021, were reviewed. The search strategy involved the use of Medline and hand-searching. Twenty two patients were treated using Kampo medicines with or without Western medicine, based on individual conditions. On the other hand, the effects of Kampo medicines as a potential preventive treatment (pre-infection), active treatment (especially in the acute and subacute stage), or treatment of sequelae to aid recovery (after infection) in the different stages of COVID-19 are being studied as research projects in the Japan Society for Oriental Medicine (JSOM). JSOM has also organized a pioneering project of clinical trials for COVID-19, some of which are now in progress.
AB - Coronavirus disease 2019 (COVID-19) spread to Japan in 2020, where the number of infected patients exceeded 250,000 and COVID-related deaths exceeded 3,500 in one year. Basic guidelines for infection control were implemented in Japan, and research and development of effective drugs and vaccines were promoted. This included considering Kampo medicine, which has a long history of treating recurring emerging viral infections. Considering the characteristics of the disease (inflammation of the upper and lower respiratory tract as well as potential neural damage and vasculitis), Kampo medicine could be considered as a treatment strategy due to its antiviral and anti-inflammatory effects induced by multiple active substances that could aid in disease prevention and recovery. In this study, case reports on the management of COVID-19 with Kampo medicine, which were published until March 31, 2021, were reviewed. The search strategy involved the use of Medline and hand-searching. Twenty two patients were treated using Kampo medicines with or without Western medicine, based on individual conditions. On the other hand, the effects of Kampo medicines as a potential preventive treatment (pre-infection), active treatment (especially in the acute and subacute stage), or treatment of sequelae to aid recovery (after infection) in the different stages of COVID-19 are being studied as research projects in the Japan Society for Oriental Medicine (JSOM). JSOM has also organized a pioneering project of clinical trials for COVID-19, some of which are now in progress.
KW - COVID-19
KW - Japan society for oriental medicine
KW - Kampo
KW - SARS-CoV-2
KW - prevention
KW - recovery
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85109154908&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109154908&partnerID=8YFLogxK
U2 - 10.3389/fphar.2021.656246
DO - 10.3389/fphar.2021.656246
M3 - Review article
AN - SCOPUS:85109154908
SN - 1663-9812
VL - 12
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - 656246
ER -
